Basic Information
PreHevbri
Regulatory Information
EMEA/H/C/005466
April 25, 2022
February 24, 2022
3
January 30, 2024
Company Information
Netherlands
Queen’s Tower Office Number 714 Delflandlaan 1 1062 EA Amsterdam
Vbi Vaccines Inc.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication PreHevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis B virus in adults. It can be expected that hepatitis D will also be prevented by immunisation with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection. The use of PreHevbri should be in accordance with official recommendations.
Overview Summary
PreHevbri is a vaccine for adults that is used in line with official recommendations to protect against hepatitis B (an infectious disease of the liver caused by hepatitis B virus). By preventing hepatitis B, the vaccine is also expected to protect against hepatitis D (another disease of the liver, caused by the hepatitis D virus). PreHevbri contains three proteins from the outer part of the hepatitis B virus.